Artelo Biosciences Announces Reverse Stock Split
Globe Newswire (Thu, 27-Aug 8:00 AM ET)
Globe Newswire (Thu, 20-Aug 8:52 AM ET)
Globe Newswire (Mon, 17-Aug 8:52 AM ET)
Artelo Biosciences Provides Business Update and Reports 2026 Second Quarter Financial Results
Globe Newswire (Thu, 13-Aug 8:00 AM ET)
Globe Newswire (Mon, 10-Aug 8:47 AM ET)
Globe Newswire (Wed, 22-Jul 8:39 AM ET)
Globe Newswire (Thu, 16-Jul 8:48 AM ET)
Globe Newswire (Tue, 14-Jul 8:47 AM ET)
Globe Newswire (Mon, 13-Jul 9:02 AM ET)
Globe Newswire (Wed, 1-Jul 8:42 AM ET)
Artelo Biosciences Inc is a United States-based development-stage biopharmaceutical company. It is engaged in the development of therapeutics that target lipid signaling pathways, including the endocannabinoid system, a family of receptors & neurotransmitters that form a biochemical communication network in the body. It is focused on discovering, licensing, developing, & commercializing treatments that control endocannabinoid systems. The company pursues technologies & programs that offer proprietary approaches to cannabinoid-based therapies, & those derived from the cannabis plant & synthetic cannabinoids, as well as new chemical entities & compounds. The firm's flagship program is designed to be a patent-protected cannabinoid drug combination treatment for a rare & orphan disease.
Artelo Biosciences trades on the NASDAQ stock market under the symbol ARTL.
As of September 4, 2026, ARTL stock price declined to $6.04 with 23,845 million shares trading.
ARTL has a beta of -2.95, meaning it tends to be less sensitive to market movements. ARTL has a correlation of 0.06 to the broad based SPY ETF.
ARTL has a market cap of $3.31 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, ARTL traded as high as $772.20 and as low as $4.68.
The top ETF exchange traded funds that ARTL belongs to (by Net Assets): VXF.
ARTL has underperformed the market in the last year with a price return of -94.9% while the SPY ETF gained +19.8%. ARTL has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -53.1% and -3.0%, respectively, while the SPY returned +2.0% and +0.6%, respectively.
ARTL support price is $5.64 and resistance is $6.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that ARTL shares will trade within this expected range on the day.
